Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 13.8% - Here's What Happened

Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report)'s stock price traded up 13.8% during mid-day trading on Friday . The company traded as high as $2.48 and last traded at $2.48. 2,742,828 shares were traded during mid-day trading, an increase of 2% from the average session volume of 2,687,534 shares. The stock had previously closed at $2.18.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Chardan Capital reiterated a "buy" rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research note on Thursday, November 14th. JMP Securities restated a "market outperform" rating and set a $5.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Cantor Fitzgerald reissued an "overweight" rating and set a $7.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Needham & Company LLC reaffirmed a "buy" rating and issued a $6.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Finally, Canaccord Genuity Group raised their price objective on Taysha Gene Therapies from $6.00 to $8.00 and gave the company a "buy" rating in a report on Friday, November 15th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $6.63.

Taysha Gene Therapies Stock Up 11.9 %

The stock has a 50 day moving average price of $1.97 and a 200-day moving average price of $2.37. The stock has a market capitalization of $500.05 million, a P/E ratio of 3.68 and a beta of 0.44. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51.

Hedge Funds Weigh In On Taysha Gene Therapies

Large investors have recently made changes to their positions in the business. Creative Planning bought a new stake in shares of Taysha Gene Therapies during the third quarter valued at approximately $28,000. Principal Financial Group Inc. purchased a new stake in Taysha Gene Therapies in the 2nd quarter worth $48,000. China Universal Asset Management Co. Ltd. grew its holdings in Taysha Gene Therapies by 79.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company's stock valued at $79,000 after purchasing an additional 17,446 shares during the last quarter. Intech Investment Management LLC bought a new position in Taysha Gene Therapies in the 3rd quarter worth about $85,000. Finally, Scientech Research LLC purchased a new stake in shares of Taysha Gene Therapies in the 2nd quarter worth approximately $97,000. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.